Nyxoah (NASDAQ:NYXH – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.03), Zacks reports. Nyxoah had a negative net margin of 1,043.93% and a negative return on equity of 51.68%.
Nyxoah Price Performance
Shares of NASDAQ:NYXH opened at $10.05 on Friday. Nyxoah has a fifty-two week low of $6.76 and a fifty-two week high of $20.00. The business has a 50-day moving average of $10.26 and a two-hundred day moving average of $9.17. The stock has a market capitalization of $342.30 million, a P/E ratio of -5.37 and a beta of 1.42. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.28 and a quick ratio of 4.95.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a “buy” rating and set a $17.00 price objective on shares of Nyxoah in a research report on Friday, December 13th.
About Nyxoah
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.
Featured Stories
- Five stocks we like better than Nyxoah
- 3 Dividend Kings To Consider
- 3 Stocks Near 52-Week Lows Ready for a Rebound
- Using the MarketBeat Stock Split Calculator
- Palantir’s Deal With Archer Aviation Keeps AI’s Future in Focus
- What is a support level?
- Joby and Archer Lead the Charge in 2025’s Urban Air Revolution
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.
